BACKGROUND: Non-steroidal Anti-Inflammatory Drugs (NSAIDs) are among the most prevalent drugs inducing hypersensitivity reactions. The aim of this analysis was to estimate the prevalence of NSAIDs-induced respiratory symptoms in population across Europe and to assess its association with upper and lower respiratory tract disorders.
METHODS: The GA(2) LEN survey was conducted in 22 centers in 15 European countries. Each of 19 centers selected random samples of 5000 adults aged 15-74 from their general population, and in three centers (Athens, Munich, Oslo) a younger population was sampled. Questionnaires including questions about age, gender, presence of symptoms of asthma, allergic rhinitis, chronic rhinosinusitis, smoking status and history of NSAIDs-induced hypersensitivity reactions were sent to participants by mail. Total 62, 737 participants completed the questionnaires.
RESULTS: The mean prevalence of NSAIDs-induced dyspnea was 1.9% and was highest in the three Polish centers [Katowice (4.9%), Krakow (4.8%) and Lodz (4.4%)] and lowest in Skopje, (0.9%), Amsterdam (1.1%) and Umea (1.2%). In multivariate analysis, the prevalence of respiratory reactions to NSAIDs was higher in participants with chronic rhinosinusitis symptoms (Odds Ratio 2.12; 95%CI 1.78-2.74), asthma symptoms in last 12 months (2.7; 2.18-3.35), hospitalization due to asthma (1.53; 1.22-1.99), and adults vs children (1.53; 1.24-1.89), but was not associated with allergic rhinitis.
CONCLUSION: Our study documented significant variation between European countries in the prevalence of NSAIDs-induced respiratory hypersensitivity reactions, and association with chronic airway diseases, but also with environmental factors. This article is protected by copyright. All rights reserved.